华大基因：2025年前三季报计提资产及信用减值损失1.96亿元 亏损同比收窄82.78%

Core Viewpoint - BGI Genomics (300676.SZ) reported a credit impairment loss of approximately 188 million yuan for the first three quarters of 2025, primarily due to expected credit loss assessments on accounts receivable and other receivables [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 2.674 billion yuan, a year-on-year decrease of 5.39% [1] - The net profit attributable to shareholders of the listed company was -21.39 million yuan, a significant narrowing of 82.78% compared to the same period last year [1] - In the third quarter alone, the company reported revenue of 1.042 billion yuan, a year-on-year increase of 9.19%, while the net loss was 27.17 million yuan, a year-on-year narrowing of 80.92% [1] Impairment Losses - The company also recognized asset impairment losses of approximately 8.8993 million yuan, with the main reason for increased credit impairment being extended payment cycles from some customers [1] - Total credit and asset impairment losses for the first three quarters of 2025 amounted to 196 million yuan, which will reduce the company's consolidated profit before tax by the same amount [1] - The company wrote off accounts receivable, inventory, and fixed assets totaling approximately 56.2848 million yuan, with all these assets fully impaired [1]